Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: Implications for perioperative hemostatic assessment.

Transfusion·2026

Same author

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

The Journal of clinical investigation·2026

Same author

The Novel C-Terminal Cystine Knot (Exon 52) VWF p.Cys2771Phe Variant Produces a Type 2A von Willebrand Factor Multimer Pattern with an Apparent Dimerization Defect.

Seminars in thrombosis and hemostasis·2026

Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026

Same author

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

bioRxiv : the preprint server for biology·2026

Same author

Reusing Blood Samples from a Hospital-based Cohort to Apixaban Plasma Concentrations.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: May 15, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.

Matthew Duvernay¹, Summer Young, David Gailani

¹Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Molecular Pharmacology

|January 12, 2013

Summary

Protease-activated receptor 4 (PAR4) stimulation yields faster and stronger thrombin generation than PAR1, indicating greater procoagulant potential. This is linked to enhanced factor V release and microparticle production, relevant for treating thrombotic disorders.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Related Experiment Videos

Last Updated: May 15, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Area of Science:

Hematology
Molecular Biology
Pharmacology

Background:

Protease-activated receptors (PARs), specifically PAR1 and PAR4, are investigated as therapeutic targets for thrombotic disorders.
Understanding the comparative efficacy of PAR1 and PAR4 in platelet activation is crucial for developing targeted antithrombotic strategies.

Purpose of the Study:

To compare the procoagulant potential of PAR1 and PAR4 activation on platelet membranes.
To elucidate the molecular mechanisms underlying differential thrombin generation mediated by PAR1 and PAR4.

Main Methods:

Stimulation of platelets with PAR1-activating peptide (AP) and PAR4-AP.
Measurement of thrombin generation in plasma.
Quantification of factor V (FV) association with platelet surface and microparticle release.
Assessment of myosin light chain phosphorylation and Rho-kinase activity.
Thrombin generation assays measuring prothrombinase complex activity.

Main Results:

PAR4-AP stimulation resulted in significantly earlier thrombin generation (up to 5 minutes) compared to PAR1-AP.
PAR4 activation led to 1.6-fold greater FV association with platelets and 3-fold greater microparticle release than PAR1.
Enhanced FV secretion and microparticle generation by PAR4-AP were linked to stronger, sustained myosin light chain phosphorylation, reducible by Rho-kinase inhibition.
PAR4-AP stimulation yielded 1.5-fold higher peak thrombin levels, with Rho-kinase inhibition partially reducing this effect.

Conclusions:

Platelet stimulation via PAR4 induces faster and more robust thrombin generation compared to PAR1.
The superior procoagulant activity of PAR4 is attributed to efficient FV release and microparticle production, driven by enhanced myosin light chain phosphorylation.
These findings highlight PAR4's significant role in hemostasis and have clinical implications for developing PAR antagonists for thrombotic conditions.